The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC)
- 15 January 2019
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 25 (2) , 839-843
Abstract
Purpose: The European Randomized Study of Screening for Prostate Cancer (ERSPC) has shown a 21% reduction in prostate cancer mortality by PSA-based screening. The aim of the study is to evaluate screening effect on prostate cancer incidence and mortality in relation to number of screening rounds attended. Experimental Design: The participants in the screening arm of the Finnish trial (31,867 men) were classified according to screening attendance in a time-dependent fashion. Initially, all men in the screening arm were regarded as nonattenders until the first screening attendance, then remained among the once-screened until the second screen and similarly for the possible third round. The control arm was the reference. Follow-up started at randomization and ended at death, emigration, or end of 2013. Prostate cancer incidence and mortality, as well lung cancer and overall mortality were evaluated. Results: Prostate cancer incidence was increased among screened men, but was not directly related to the number of screening rounds. Prostate cancer mortality was decreased in men screened twice or three times, but did not materially differ in those who did not attend the screening, and in men screened once compared with the control arm. The largest mortality reduction was in men screened three times [HR 0.17; 95% confidence interval (CI), 0.09–0.33]. However, a reduction was also seen in lung cancer (HR 0.59; 95% CI, 0.47–0.73) and overall mortality (HR 0.56; 95% CI, 0.52–0.60). Conclusions: Assuming a similar relative reduction being due to selection bias and screening in prostate cancer as other causes of death (40% reduction), approximately half of the observed prostate cancer mortality reduction by repeated screening is likely to be noncausal and a real screening effect may account for up to 40% reduction in men screened three times. Prostate cancer mortality reduction can only be achieved by repeated screening cycles.Keywords
All Related Versions
Funding Information
- Research Council of Finland (260931)
This publication has 15 references indexed in Scilit:
- Number of Screening Rounds and Postscreening Prostate Cancer Incidence: Results from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer StudyEuropean Urology, 2016
- Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-upThe Lancet, 2014
- Prostate Cancer Mortality in the Finnish Randomized Screening TrialJNCI: Journal of the National Cancer Institute, 2013
- Overdiagnosis in CancerJNCI: Journal of the National Cancer Institute, 2010
- Socioeconomic status and prostate cancer incidence and mortality rates among the diverse population of CaliforniaCancer Causes & Control, 2009
- 15-Year Followup of a Population Based Prostate Cancer Screening StudyJournal of Urology, 2009
- Screening and Prostate-Cancer Mortality in a Randomized European StudyNew England Journal of Medicine, 2009
- Prostate cancer incidence and survival in relation to education (United States)Cancer Causes & Control, 2004
- Results of a randomized, population‐based study of biennial screening using serum prostate‐specific antigen measurement to detect prostate carcinomaCancer, 2004
- The Finnish trial of prostate cancer screening: where are we now?BJU International, 2003